CONBA(SH:600572) Shang Hai Zheng Quan Bao·2025-08-15 19:30Group 1 - The core point of the announcement is that Zhejiang Kangnbei Pharmaceutical Co., Ltd. plans to reduce the shareholding of its major shareholder, Kangnbei Group Co., Ltd., through a centralized bidding method [1][2]. - Kangnbei Group holds 254,431,171 shares, accounting for 10.079% of the total share capital of 2,524,267,371 shares as of August 14, 2025 [1]. - The planned reduction will not exceed 25,242,673 shares, which is 1% of the total share capital, and the selling price will be determined based on market conditions at the time of the sale [1][2]. Group 2 - Kangnbei Group has made commitments regarding its shareholding and will comply with relevant laws and regulations during the reduction process [3]. - The reduction plan is consistent with previous commitments made by Kangnbei Group during the company's initial public offering and other related matters [3]. - The company will ensure that the reduction plan is implemented legally and in compliance with the Shanghai Stock Exchange regulations [4].